Company Filing History:
Years Active: 2015
Title: Nathan Ihle: Innovator in Cancer Treatment
Introduction
Nathan Ihle is a prominent inventor based in Bothell, WA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of antibody-drug conjugates. His work focuses on improving therapeutic regimens for patients suffering from CD30-expressing cancers.
Latest Patents
Nathan Ihle holds a patent for "Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates." This patent outlines methods for treating CD30-expressing cancers by administering a weekly dose of an antibody-drug conjugate compound. The dosage ranges from about 0.8 mg/kg to about 1.8 mg/kg, providing a targeted approach to cancer therapy.
Career Highlights
Nathan Ihle is associated with Seattle Genetics, Inc., a leading biotechnology company specializing in developing innovative cancer therapies. His work at the company has been instrumental in advancing treatment options for patients with specific cancer types.
Collaborations
Nathan collaborates with notable colleagues, including Eric Sievers and Dana Kennedy. Their combined expertise contributes to the ongoing research and development efforts at Seattle Genetics, Inc.
Conclusion
Nathan Ihle's contributions to cancer treatment through his innovative patent and work at Seattle Genetics, Inc. highlight his commitment to improving patient outcomes. His research continues to pave the way for advancements in targeted cancer therapies.